MedPath

Cyproheptadine in Schizophrenia

Phase 3
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT20100127003210N22
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
30
Inclusion Criteria

Ages 18-65 years
Diagnosis of schizophrenia or schizoaffective disorder (Deppresive type) based on DSM-V
Taking Risperidone as an Antipsychotic
Fill in the consent

Exclusion Criteria

Antipsychotic treatment other than Risperidone
History of non-response to second generation antipsychotic treatment
Drug abuse
Thyroid Disorder
Pregnancy and Lactation

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Positive and Negative Syndrome. Timepoint: At the beginning of the study, the first week, the second week, the fourth week, the sixth week. Method of measurement: PANSS Questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath